From: Radiogenic angiosarcoma of the breast: case report and systematic review of the literature
Author | Year | Treatment modalities (Initial) | Treatment modalities (Recurrence) | Chemotherapy (n)/ regimen | RXT (n)/ gray | Recurrence-Free survival (m) | Overall survival (m) |
---|---|---|---|---|---|---|---|
Fodor [4] | 2006 | MAS (8) | S + CHXT (1) | 1/DOCE | – | 16 | 26 |
Marchal [5] | 1999 | MAS (4);MAS + CHXT (2); MAS + RXT (2);MAS + S (1) | S (1);RXT; CHXT (7) | 2/− | 3/30;45a | 7 | 15 |
D’Angelo [6] | 2013 | MAS (65);S (13)a; CHXT (9) | CHXT (23) | 23/DOX (9), PAC (3), SORA (3), BRIV (2), IFO (1), DOX + PAC (1), GEM+DOCE (1), SIR (1) | – | 16 | 36 |
Strobbe [9] | 1998 | MAS (20);MAS + S (1) | S (7) | – | – | 13 | 27 |
Smith [12] | 2014 | MAS (6);MAS + RXT (8) | RXT (6) | – | 14/45 (2);60 (3);75 (9) |  | 97 |
West [19] | 2005 | MAS (2);MAS + RXT (1);MAS + CHXT (1) | S (1); CHXT (1) | 2/TAX;ADR | 2/− | 26;6;3;5 | 26;19;12;6 |
Rao [20] | 2003 | MAS (3) | S + CHXT (1) | – | – | 41;3;7 | 41;12;7 |
Polgár [21] | 2001 | MAS (1);NT (1) | MAS (1) | – | – | 36;4 | 36;4 |
Vesoulis [22] | 2000 | MAS + CHXT (1) |  | 1/− | – | – | – |
Wijnmaalen [24] | 1993 | MAS (2);MAS + S (1) | S (1) | – | – | 7;16;30 | 7;30;34 |
Otis [27] | 1986 | S (2) | – | 1/− | – | 2 | – |
Armengot-Carbó [29] | 2012 | MAS (1) | – | – | – | 9 | 9 |
Fernández [30] | 2006 | MAS (2) | S (1) | – | – | 8;50 | 10;50 |
Colville [33] | 2000 | S (1) | MAS;S;RXT (1) | – | 1/40 | 8 | 20 |
Hogewind [34] | 2004 | MAS (2) | S (1) | – | – | 4;24 | 4,24 |
Williams [35] | 2004 | MAS (1) | – | – | – | 5 | 5 |
Deutsch [37] | 2003 | MAS + S (1) | S;RXT (1) | – | 1/− | 4 | 23 |
Hildebrandt [41] | 2001 | MAS (1) | S (1) | – | – | 16 | 23 |
Esler-Brauer [7] | 2007 | MAS (1) | – | – | – | 45 | 45 |
Catena [42] | 2006 | MAS (1) | – | – | – | 10 | 10 |
Moe [43] | 2007 | MAS (1) | S;CHXT (1) | 1/DOX;IFO | – | 2 | 20 |
Hodgson [45] | 2007 | MAS (25) |  | – | – | – | – |
Soldić [48] | 2009 | MAS | – | – | – | 16 | 16 |
Zucali [53] | 1994 | S (1);MAS (2); MAS + S (1) | S + RXT (1);CHXT (1) | 1/− | 1/60 | 96;4;13 | 96;7;24 |
Aydogdu [54] | 1996 | MAS (1) | – | – | – | 3 | – |
Weber [56] | 1995 | S (2);RXT + CHXT (1) | RXT;CHXT (1) | 1/5-FU, DOX | – | 36;24 | 36;24 |
Majeski [57] | 2000 | MAS + S (1) | S (1) | – | – | 26 | 29 |
Nakamura [60] | 2007 | MAS + CHXT (1) | – | 1/PAC | – | 15 | 15 |
Billings [64] | 2004 | MAS (10); S (10)a | CHXT (4) | 4/− | – | – | 42 |
Navarro Cecilia [67] | 2015 | MAS (1) | S (1) | – | – | 1 | 7 |
Uryvaev [68] | 2015 | MAS (3);MAS + RXT (3) | RXT (2);CHXT (3) | 3/ADR + IFO (1); DOX + PAC (2) | 3/50 (2);16 (1) | – | 43 |
Gennaro [69] | 2010 | MAS (9) | – | 5/ADR + IFO | – | – | – |
Feigenberg [8] | 2002 | MAS (3) | RXT (3) | – | 3/60 (2);50 (1) | 2;1;22 | 41;60;22 |
Hui [71] | 2012 | MAS (1);MAS + RXT (4);MAS + CHXT (3) | – | 3/PAC | – | – | – |
Adhikari [72] | 2002 | S + RXT + CHXT (1) | S (1) | 1/ADR + CYC | 1/50 | 13 | 16 |
Hanasono [74] | 2005 | S (1) | S,CHXT (1) | – | – | 2 | 13 |
Mocerino [75] | 2016 | MAS (1) | S;CHXT;RXT (1) | 1/BLEO;DOX | 1/60 | 12 | 24 |
Moskaluk [78] | 1992 | S (1) | MAS (1) | – | – | 24 | 96 |
Pooled Analysis | – | MAS (83%); S (13%); CHXT (4%) (adjuvant); RXT (6%) (adjuvant) | CHXT (58%); S (33%); RXT (30%)b | – | – | 15.9 | 27.4 |